Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecirasib Combined With Ivonescimab in 1L KRAS G12C-mutated NSCLC
NCT07339839Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
01
Overview
A Phase 2 trial of glecirasib, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
glecirasibivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07339839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339839.